Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Disease progression | D018450 | — | — | — | 1 | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | — | — | — | 1 |
Nervous system diseases | D009422 | — | G00-G99 | — | 1 | — | — | — | 1 |
Autoimmune diseases of the nervous system | D020274 | — | — | — | 1 | — | — | — | 1 |
Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | 1 | — | — | — | 1 |
Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Zotiraciclib |
INN | zotiraciclib |
Description | Zotiraciclib (TG02) is a potent oral spectrum selective[clarification needed] kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib.
Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property. Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas.
|
Classification | Small molecule |
Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1 |
PDB | — |
CAS-ID | 1204918-72-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1944698 |
ChEBI ID | — |
PubChem CID | 16739650 |
DrugBank | — |
UNII ID | 40D08182TT (ChemIDplus, GSRS) |